Jan. 13 Quick Takes: TREM2 setback for Denali
Plus BMS-Prellis, Lysogene-Sarepta, Biohaven-KU Leuven, Castle Creek-Novavita and Idorsia
Shares of neurology company Denali Therapeutics Inc. (NASDAQ:DNLI) fell 12% to $33.86 on Thursday after disclosing that FDA placed a clinical hold on an IND for DNL919, its antibody transport vehicle (ATV)-enabled mAb targeting TREM2. The biotech had expected to start the first clinical trial for the program this half to treat Alzheimer’s disease. In December, Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) exercised its option to co-develop and co-commercialize DNL919.
Bristol Myers Squibb Co. (NYSE:BMY) will use the EXIS externalized human immune system from Prellis Biologics Inc. to develop antibody libraries against select targets. The system is based on human lymph node organoids. Terms are undisclosed, but Prellis is to receive an upfront payment and research funding, and is eligible for milestones and royalties...